Why the study?
LA arrhythmogenic substrate beyond the pulmonary veins plays a crucial role in maintaining AF, but predictors of voltage-defined LA fibrosis in patients with LSPAF undergoing catheter ablation are not fully established.
What clinical and non-invasive parameters predict the presence of voltage-defined left atrial fibrosis in patients with long-standing persistent atrial fibrillation?
What clinical and non-invasive parameters predict the presence of voltage-defined left atrial fibrosis in patients with long-standing persistent atrial fibrillation?
In patients with long-standing persistent AF, clinical parameters such as female sex, valvular heart disease, and a CHA₂DS₂-VASc score ≥ 4 independently predict left atrial fibrosis, whereas AF duration and LA size do not.
Answers are grounded in this paper and cite their sources.
May identify fibrosis markers in LSPAF; leaves open whether targeting them improves ablation outcomes.
BACKGROUND: Left atrial (LA) arrhythmogenic substrate beyond the pulmonary veins (PV) seems to play a crucial role in the maintenance of atrial fibrillation (AF). The aim of this study was to evaluate the association of selected parameters with the presence and extent of voltage-defined LA fibrosis in patients with long-standing persistent AF (LSPAF) undergoing catheter ablation. METHODS: One hundred and sixteen consecutive patients underwent high density-high resolution voltage mapping of the LA with a multielectrode catheter following PV isolation and restoration of sinus rhythm with cardioversion. A non-invasive dataset, such as clinical variables, two-and three-dimensional echocardiography determined LA size and function and fibrillatory-wave amplitude on a standard surface electrocardiogram were obtained during AF before ablation. RESULTS: Low-voltage areas (LVA; 15 cm² [IQR 8-31]) were detected in 56% of patients. Twenty nine percent of them presented mild, 43% moderate and 28% severe global LVA burden. In univariate analysis, age ≥ 57 years old, female sex, body surface area ≤ 1.76 m², valvular heart disease, moderate mitral regurgitation, chronic coronary syndrome, hypothyroidism, CHA₂DS₂-VASc score ≥ 3 and ≥ 4 predicted the presence of LVA. In multivariate analysis only female sex, valvular heart disease and CHA₂DS₂-VASc ≥ 4 remained statistically significant. AF duration, LA size and function and fibrillatory-waves amplitude were neither associated with the prediction of the LVA, nor severe LVA burden. CONCLUSIONS: A LSPAF diagnosis does not indicate the presence of voltage defined fibrosis in many cases. Simple non-invasive screening of the LSPAF population could predict LVA prevalence.
No takes yet. Share an insight, caveat, or question.
Kiedrowicz et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: